Of the 300 patients in the PARCER trial, 93 faced grades ≥2 adverse events (3D-CRT = 59, IG-IMRT = 34). Patients in the 3D-CRT and IG-IMRT arms spent an average of 2.39 years and 1.96 years in ...
According to preliminary data from a multi-institution Phase III trial intensity modulated proton therapy (IMPT) achieved similar clinical outcomes and offered significant patient benefits when ...
Intensity-modulated radiotherapy is as good as proton beam therapy for treating people with head and neck cancer, according to the results of a Cancer Research UK-funded clinical trial. The TORPEdO ...
Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not ...